Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 11151 clinical trials
TrialXAutomationRun2235  

TrialXAutomationRun2235

  • 0 views
  • 14 Mar, 2022
TrialXAutomationRun2237  

TrialXAutomationRun2237

  • 0 views
  • 14 Mar, 2022
TrialXAutomationRun2238  

TrialXAutomationRun2238

  • 0 views
  • 14 Mar, 2022
TrialXAutomationRun2240  

TrialXAutomationRun2240

  • 0 views
  • 14 Mar, 2022
TrialXAutomationRun2241  

TrialXAutomationRun2241

  • 0 views
  • 14 Mar, 2022
TrialXAutomationRun2242  

TrialXAutomationRun2242

  • 0 views
  • 14 Mar, 2022
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Primary Objective: To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B Secondary Objective: To characterize the safety and tolerability To characterize the pharmacokinetics (PK)

severe haemophilia a
haemophilia a
fitusiran
antihemophilic factor
hemophilia
  • 0 views
  • 04 Dec, 2020
  • 11 locations
Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants  

To assess the immune response (serotype specific IgG concentration) of the SP0202 formulations and Prevnar 13 1 month after the administration of one dose in toddlers (Groups 1-4) To assess the immune response (serotype specific IgG concentration) of the SP0202 formulations and Prevnar 13 1 month after the administration of …

  • 0 views
  • 17 Nov, 2020
  • 31 locations
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Primary Objective: To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B Secondary Objective: To characterize the safety and tolerability To characterize the pharmacokinetics (PK)

severe haemophilia a
haemophilia a
fitusiran
antihemophilic factor
hemophilia
  • 0 views
  • 04 Dec, 2020
  • 6 locations
Check Site Phone Validation  

Check Site Phone Validation

  • 0 views
  • 16 Feb, 2024
  • 15 locations